Evidence map›Paper›PMID 25255025›Full record

ArticlePLoS pathogens2014

Myeloid derived hypoxia inducible factor 1-alpha is required for protection against pulmonary Aspergillus fumigatus infection.

Kelly M Shepardson, Anupam Jhingran, Alayna Caffrey, Joshua J Obar, Benjamin T Suratt, Brent L Berwin, Tobias M Hohl, Robert A Cramer

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Studies in mycology · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Kelly M ShepardsonDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America.
Anupam JhingranInfectious Disease Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Alayna CaffreyDepartment of Microbiology and Immunology, Montana State University, Bozeman, Montana, United States of America.
Joshua J ObarDepartment of Microbiology and Immunology, Montana State University, Bozeman, Montana, United States of America.
Benjamin T SurattDepartment of Medicine, University of Vermont College of Medicine, Burlington, Vermont, United States of America.
Brent L BerwinDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America.
Tobias M HohlInfectious Disease Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Robert A CramerDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America.
Dartmouth College · USMemorial Sloan Kettering Cancer Center · USMontana State University · USUniversity of Vermont · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
VIRUSES: FROM PARTICLES TO PROTEOMICSP20RR020185 · NCRR · MONTANA STATE UNIVERSITY - BOZEMAN · PI VOYICH, JOVANKA M · 2004 to 2011
$17.0M
TRANSLATIONAL RESEARCH COREP30GM106394 · NIGMS · DARTMOUTH COLLEGE · PI O'TOOLE, GEORGE A. · 2013 to 2017
$6.1M
INITIATION OF THE IMMUNE RESPONSE TO ASPERGILLUS FUMIGATUSR01AI093808 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI HOHL, TOBIAS M · 2011 to 2020
$4.9M
Center for Molecular, Cellular, and Translational ImmunologyP30GM103415 · NIGMS · DARTMOUTH COLLEGE · PI GREEN, WILLIAM R · 2012 to 2015
$4.7M
INITIATION OF THE IMMUNE RESPONSE TO ASPERGILLUS FUMIGATUSR37AI093808 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI TOBIAS M HOHL · 2021 to 2026
$4.2M
Center for Zoonotic and Emerging Infectious DiseasesP20GM103500 · NIGMS · MONTANA STATE UNIVERSITY - BOZEMAN · PI QUINN, MARK T · 2012 to 2013
$4.2M
Hypoxia Adaptation and Fungal Virulence of Aspergillus fumigatusR01AI081838 · NIAID · MONTANA STATE UNIVERSITY - BOZEMAN · PI CRAMER, ROBERT ANDREW · 2009 to 2017
$2.9M
RENAL FUNCTION AND DISEASET32DK007301 · NIDDK · DARTMOUTH COLLEGE · PI STANTON, BRUCE A. · 1986 to 2014
$2.3M
CENTER FOR MOLECULAR, CELLULAR, AND TRANSLATIONAL IMMUNOLOGYP30RR032136 · NCRR · DARTMOUTH COLLEGE · PI GREEN, WILLIAM R · 2011 to 2011
$1.2M
Dissection of Macrophage Antifungal Activity against Aspergillus fumigatusR21AI105617 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI HOHL, TOBIAS M · 2013 to 2014
$473k
NCI NIH HHS 5 P30 CA023108NCI NIH HHS P30 CA023108NCRR NIH HHS 5P30RR032136-02NCRR NIH HHS P20 RR020185NCRR NIH HHS P30 RR032136NCRR NIH HHS RR020185NIAID NIH HHS R01 AI081838NIAID NIH HHS R01 AI093808NIAID NIH HHS R01AI093808NIAID NIH HHS R01AI81838NIAID NIH HHS R21 AI105617NIAID NIH HHS R37 AI093808NIDDK NIH HHS 2T32DK007301-31A2NIDDK NIH HHS T32 DK007301NIGMS NIH HHS 1P30GM106394-01NIGMS NIH HHS 5P30GM103415-03NIGMS NIH HHS 8 P30 GM103415-02NIGMS NIH HHS P20 GM103500NIGMS NIH HHS P20-GM103500NIGMS NIH HHS P30 GM103415NIGMS NIH HHS P30 GM106394PHS HHS AIR21105617
6 · The paper itself

Abstract

Hypoxia inducible factor 1α (HIF1α) is the mammalian transcriptional factor that controls metabolism, survival, and innate immunity in response to inflammation and low oxygen. Previous work established that generation of hypoxic microenvironments occurs within the lung during infection with the human fungal pathogen Aspergillus fumigatus. Here we demonstrate that A. fumigatus stabilizes HIF1α protein early after pulmonary challenge that is inhibited by treatment of mice with the steroid triamcinolone. Utilizing myeloid deficient HIF1α mice, we observed that HIF1α is required for survival and fungal clearance early following pulmonary challenge with A. fumigatus. Unlike previously reported research with bacterial pathogens, HIF1α deficient neutrophils and macrophages were surprisingly not defective in fungal conidial killing. The increase in susceptibility of the myeloid deficient HIF1α mice to A. fumigatus was in part due to decreased early production of the chemokine CXCL1 (KC) and increased neutrophil apoptosis at the site of infection, resulting in decreased neutrophil numbers in the lung. Addition of recombinant CXCL1 restored neutrophil survival and numbers, murine survival, and fungal clearance. These results suggest that there are unique HIF1α mediated mechanisms employed by the host for protection and defense against fungal pathogen growth and invasion in the lung. Additionally, this work supports the strategy of exploring HIF1α as a therapeutic target in specific immunosuppressed populations with fungal infections.

Indexed as

AnimalsApoptosisAspergillus fumigatusBlotting, WesternCell MovementCell ProliferationCells, CulturedChemokine CXCL1HumansHypoxia-Inducible Factor 1, alpha SubunitImmunity, InnateImmunoenzyme TechniquesInflammationLungMacrophagesMiceChemokine CXCL1Cxcl1 protein, mouseHypoxia-Inducible Factor 1, alpha SubunitRNA, Messenger

Identifiers

PMID25255025
PMCPMC4177996
OpenAlexW2057524350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.